●
Earnings Feed
Filings
Companies
Insiders
Pricing
Blog
⌘
K
Login
Start Free
EASTON PHARMACEUTICALS INC.
·
10-K
Dec 22, 4:37 PM ET
Share
Compare
EASTON PHARMACEUTICALS INC. 10-K
Loading document...
Share
More
Contents
84
TABLE OF CONTENTS
PART I
PART II
PART III
PART IV
SIGNATURES
PART I
Item 1. Business.
Product and Market Overview
Past and Present Product Development
Recent Initiatives
1124123 Ontario Limited Acquisition
2315446 Ontario Inc. Acquisition (Cobourg Property)
iBliss Acquisition
BAYER Sub-Distribution Agreement
Mexico & Latin America – Licensed Diagnostic / Treatment Products
Patented Exclusive Women’s Health Products from Common Sense LTD:
Vaginal Discharge Diagnostic Test and Amniotic Fluid Leak Test
Generic Cancer Drugs
Drug Delivery Technology
Patents and Trademarks
1A. Risk Factors.
Risks Related to Our Business
Our lack of sales and operating history makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance.
We are subject to intense competition
We are potentially subject to unknown regulations
Demand for our products cannot be predicted
Risks Related to Our Common Stocks
We do not expect to pay dividends in the foreseeable future.
Our common stock is subject to price volatility unrelated to our operations.
1B. Unresolved Staff Comments.
Item 2. Properties.
Item 3. Legal Proceedings.
Item 4. Mine Safety Disclosures.
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Holders
Dividends
Unregistered Sales of Securities and Use of Proceeds
Transfer Agent
Item 6. Selected Financial Data
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Overview
Revenue
Operating Expenses
Net Loss
Cost of Revenues
7A. Quantitative and Qualitative Disclosures About Market Risk.
Item 8. Financial Statements and Supplementary Data.
Table of Contents
Balance Sheets
Statement of Operations
Statement of Stockholders’ Equity (Deficit)
Statement of Cash Flows
Notes to Financial Statements
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
9A. Controls and Procedures.
Management’s Report on Internal Control over Financial Reporting
9B. Other Information.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
DIRECTORS AND EXECUTIVE OFFICERS
Section 16(a) Beneficial Ownership Reporting Compliance
CORPORATE GOVERNANCE MATTERS
Item 11. Executive Compensation.
Summary Compensation Table
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
LOANS PAYABLE
DUE TO RELATED PARTIES
Item 14. Principal Accountant Fees and Services.
Audit Fees
Audit Related Fees
Tax Fees
All Other Fees
PART IV
Item 15. Exhibit and Financial Statement Schedules.
Item 16. Form 10–K Summary.
SIGNATURES
EASTON PHARMACEUTICALS, INC.
EXHIBIT 31.1
CERTIFICATION
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Contents
Share
More
Download PDF